Uberflip

uberflip.com

Uberflip is the world’s #1 Content Experience Platform (CEP). With tools to aggregate all your marketing content, they empower B2B marketing and sales teams to create personalized content experiences to engage accounts, nurture prospects, and convert leads, without the help of IT. It’s their mission to put control back in the hands of marketing teams to deliver high-converting experiences, that put the customer front and center.

C-Suite On Deck

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience.

Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies ...

Events

International Conference on Pharmacology (ICPHARMA-23)

Conference

28th Medicines for Europe Annual Conference 2023

Conference

Pharma MES 2023

Conference

Effective Integration of SDOH in Pharmacy and Interprofessional Curricula

Webinar

2023 PDA Pharmaceutical Microbiology Conference

Conference

Webinar on Artificial Intelligence in pharmacy practice

Webinar

Related News

PARALLEL'S SURTERRA WELLNESS STORES TO INTRODUCE NEW PRODUCTS INCLUDING EDIBLES IN FLORIDA

Prnewswire | August 31, 2020

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of e...

BUSINESS INSIGHTS, PHARMACY MARKET

SOCIETAL CDMO SELECTED BY LONGBOARD PHARMACEUTICALS TO PROVIDE CDMO SERVICES TO SUPPORT CLINICAL DEVELOPMENT OF LP352

Globenewswire | April 06, 2023

Societal CDMO, Inc. a contract development and manufacturing organization announced that it has been selected by Longboard Pharmaceuticals, Inc. to provide CDMO services. The agreement spans a range of Societal CDMO’s offerings including technology transfer and analytical method validation activities to support Longboard’s lead asset, LP352, a 5-HT2C receptor superagonist. LP352 is currently being evaluated in the PACIFIC Study, a Phase 1b/2a basket trial, in participants with ...

BUSINESS INSIGHTS, PHARMACY MARKET

CELLWORKS ANNOUNCES EXPANSION INTO PRECISION PHARMA

Cellworks Group | January 13, 2023

Cellworks Group Inc., a pioneer in personalized therapy biosimulation, announced the introduction of its precision drug development business units. These units will use predictive biosimulation to shorten drug development time-to-market and revive previously researched but disapproved pharmaceutical assets. The two new business units will use Cellworks' computational biology model (CBM) and biosimulation platform to predict responses to pharmaceutical intervention...

PHARMA TECH

NUCLEAI ANNOUNCES A PARTNERSHIP WITH SIRONA DX FOR AI-DRIVEN DISCOVERY OF NOVEL SPATIAL BIOMARKERS IN SOLID TUMORS

Nucleai and Sirona Dx | July 14, 2022

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s leading multiplex assay development expertise to identify novel spatial signatures in high-pl...